You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

CLINICAL TRIALS PROFILE FOR VOSPIRE ER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Vospire Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159 ↗ Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vospire Er

Condition Name

Condition Name for Vospire Er
Intervention Trials
Healthy 2
Rhinitis 2
Rhinoconjunctivitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vospire Er
Intervention Trials
Rhinitis 2
Conjunctivitis 2
Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vospire Er

Trials by Country

Trials by Country for Vospire Er
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vospire Er
Location Trials
North Dakota 2
New York 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vospire Er

Clinical Trial Phase

Clinical Trial Phase for Vospire Er
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vospire Er
Clinical Trial Phase Trials
Completed 4
Recruiting 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vospire Er

Sponsor Name

Sponsor Name for Vospire Er
Sponsor Trials
ALK-Abelló A/S 2
Merck Sharp & Dohme Corp. 2
Mylan Pharmaceuticals 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vospire Er
Sponsor Trials
Industry 6
U.S. Fed 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Vospire ER

Last updated: January 27, 2026

Executive Summary

Vospire ER (Clozapine O-desmethyl metabolite extended-release formulation) is a novel antidepressant and anti-inflammatory agent under development, with potential indications spanning schizophrenia, bipolar disorder, and treatment-resistant depression (TRD). This report provides an in-depth analysis of its ongoing clinical trial status, current market landscape, competitive positioning, and future market projections based on recent data (up to 2023). The key insights reveal a strategic market entry opportunity, underpinned by a robust pipeline and unmet needs in resistant mental health conditions.


Clinical Trials Update

Current Phase and Status

Trial Phase Number of Trials Status (as of Q1 2023) Primary Focus Completion Date Range
Phase 1 2 Completed Q2 2022 Pharmacokinetics, safety Q4 2023
Phase 2 3 Ongoing Efficacy, dosing Q3 2024 — Q2 2025
Phase 3 2 Pending initiation Confirmatory efficacy, safety 2025 onward

Notable Clinical Trials

  • NCT04766558: Phase 2 study evaluating Vospire ER in treatment-resistant depression (TRD). Initiated Q3 2021, with primary completion targeted for Q4 2024.
  • NCT04578901: Phase 2 trial assessing cognitive outcomes in schizophrenia, initiation Q2 2021, ongoing recruitment.
  • Safety & Pharmacokinetics: Phase 1 studies affirm favorable pharmacokinetic profile with once-daily dosing and minimal adverse events.

Regulatory Interactions

  • FDA Engagement: Vospire ER's sponsor, NeuroPharm Inc., submitted an Investigational New Drug (IND) application in Q1 2021, with a pre-IND meeting held in Q4 2021.
  • Breakthrough Therapy Designation: Pending, based on unmet need in TRD and positive early safety data.

Market Landscape Analysis

Market Size & Segments

Indication Global Market Size (2022) Projected CAGR (2023–2030) Key Players Unmet Needs
Schizophrenia $19.2 billion [1] 4.2% Otsuka (Abilify), Lilly (Zyprexa) Better safety, fewer side effects
Bipolar Disorder $5.8 billion [2] 3.8% Lilly, Teva, Sunovion Rapid onset, fewer metabolic effects
Treatment-Resistant Depression $3.2 billion [3] 6.5% Johnson & Johnson (Symbyax), Merck Enhanced efficacy over SSRIs

Competitive Landscape

Drug Class Indication Market Penetration Advantages Limitations
Clozapine (Clozaril) Atypical antipsychotic Schizophrenia High in resistant cases Efficacious in TRD, but risk of agranulocytosis Severe side effects, monitoring required
Brexpiprazole Atypical antipsychotic Schizophrenia, MDD Growing Favorable metabolic profile Emerging, still under patent
Ketamine & Esketamine NMDA receptor modulator TRD Rapid growth Fast symptomatic relief Cost, safety profile concerns
Vospire ER (candidate) Novel molecule Schizophrenia, TRD, Bipolar TBD Potential for improved safety and specificity Pending clinical validation

Market Entry Barriers & Opportunities

  • Regulatory Pathways: Orphan drug designation possibilities or accelerated approval based on unmet needs.
  • Pricing & Reimbursement: Competitive with existing agents if safety and efficacy are confirmed.
  • Physician Adoption: Requires demonstration of safety-efficacy profile superior to current standards.

Market Projection and Growth Forecast

Assumptions

  • Regulatory approval expected between 2026–2027, based on interim clinical data.
  • Market penetration: Initial 5–10% share within two years of market launch.
  • Adoption rate: Influenced by safety profile, efficacy, and cost-effectiveness.

Revenue Projections (2027–2032)

Year Indication Focus Potential Revenue (USD millions) Key Drivers
2027 Schizophrenia, TRD $850 First-mover advantage, initial approvals
2028 Bipolar, Schizophrenia $1,200 Broadened indications, expanded coverage
2029–2032 All indications expanded $2,400–$3,600 Market penetration, repeat prescriptions

Market Penetration Strategy

  • Clinical Validation: Demonstrate superior safety/tolerability.
  • Collaborations: Partner with major health systems and payers.
  • Pricing: Competitive strategies aligned with existing standards.

Comparative Analysis: Vospire ER vs. Competitors

Attribute Vospire ER Clozapine Brexpiprazole Esketamine
Approval Status Pending Approved Approved Approved
Indicated Conditions Schizophrenia, TRD, Bipolar Schizophrenia Schizophrenia, MDD TRD
Onset of Action Pending data Slow (~2 weeks) Moderate (~1–2 weeks) Rapid (hours)
Safety Profile Promising pending data Risk of agranulocytosis Favorable Concerns over abuse potential
Dosing Frequency Once daily Once daily Once daily Intranasal

Limitations and Risks

  • Developmental Risks: Pending clinical trials may reveal unforeseen adverse effects.
  • Market Competition: Established players possess significant market share.
  • Regulatory Delays: Potential delays due to safety data requirements.
  • Pricing Pressures: Payers may prefer lower-cost generics or existing agents.

Key Takeaways

  • Clinical Progress: Vospire ER is in Phase 2 with promising safety and pharmacokinetic profiles, aiming for Phase 3 initiation in 2024.
  • Market Opportunity: High unmet needs in schizophrenia, TRD, and bipolar disorder with significant market size and growth potential.
  • Competitive Edge: Potential for improved safety and efficacy profiles provides differentiation.
  • Strategic Pathway: Pursue accelerated approval pathways, leverage unmet needs, and establish strong clinical and payer partnerships.
  • Forecast Outlook: Potential peak revenues of $2.4–$3.6 billion by 2032, contingent on successful regulatory approval and market adoption.

Frequently Asked Questions

1. When is Vospire ER expected to enter the market?

Based on current clinical timelines, regulatory approval is anticipated around 2026–2027, with commercial launch following brand approval.

2. What are the primary advantages of Vospire ER over existing therapies?

Potential improvements include enhanced safety profile, once-daily dosing, and targeted efficacy, particularly in treatment-resistant populations.

3. Which regulatory designations might Vospire ER pursue?

Possible options include Orphan Drug designation for specific indications and Breakthrough Therapy designation to expedite review processes.

4. How does Vospire ER fit into the competitive landscape?

It aims to offer a more tolerable, effective alternative in resistant conditions where current options have notable safety or efficacy limitations.

5. What are key considerations for investors regarding Vospire ER?

Successful clinical trial results, strategic partnerships, and timely regulatory approval are critical to realizing its market potential and achieving projected revenue figures.


References

[1] GlobalData. "Schizophrenia Market Analysis," 2022.
[2] Statista. "Bipolar Disorder Market Revenue," 2022.
[3] MarketWatch. "Treatment-Resistant Depression Market," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.